Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Weight management and incretin-based pharmacotherapy

14 evidence topics · 8 sources

Tirzepatide label: week 52 AHI results in Studies 5 and 6, modified intent-to-treat population, hypopneas scored with 4% oxygen desaturation
MeasureStudy 5 placebo (N = 120)Study 5 ZEPBOUND MTD (N = 114)Study 5 difference from placebo (95% CI)Study 6 placebo (N = 114)Study 6 ZEPBOUND MTD (N = 119)Study 6 difference from placebo (95% CI)
AHI change from baseline (events/hr)“-5.3”“-25.3”“-20 (-25.8, -14.2)”“-5.5”“-29.3”“-23.8 (-29.6, -17.9)”
Percent change in AHI from baseline“-3”“-50.7”“-47.7 (-65.8, -29.6)”“-2.5”“-58.7”“-56.2 (-73.7, -38.7)”
Percent of participants with ≥50% reduction in AHI“19”“61.2”“42.8 (30.8, 54.8)”“23.3”“72.4”“48.6 (36.6, 60.7)”
Percent with AHI <5 or AHI 5-14 and ESS ≤10“15.9”“42.2”“28.7 (18.3, 39.2)”“14.3”“50.2”“33.2 (22.1, 44.3)”
SURMOUNT-OSA: AHI change at week 52, treatment-regimen estimand, hypopneas scored with 4% oxygen desaturation